KBI BioPharma, a provider of contract biopharmaceutical processes and services, is beefing up its management team with three additional hires.
Joing KBI are:
KBI launched its biopharmaceutics practice earlier this summer when it opened new laboratories at its 370,000 sq. ft. offices in Durham. It will focus on a variety of contract-basis services for analytical method development and validation; preformulation; liquid and lyophilized formulation development; biophysical characterization and accelerated and cGMP (Current Good Manufacturing Practices) stability testing services.
“We are constantly striving to meet new challenges by adapting and aligning our organization to maximize our capabilities and better serve our customers and business partners,” said Tony Laughrey, president and chief executive officer of KBI BioPharma, in a statement. “Executives with this level of experience, and leadership will be instrumental in ensuring that KBI achieves its growth targets and delivers ‘Best-of-Breed’ biopharmaceutical process development, production and technology solutions to customers around the globe.”
Lee has worked previously with Diosynth Biotechnology and North American Vaccine.
Bedu-Addo’s resume includes positions with Elan Pharmaceuticals, Schering-Plough, Diosynth and Cardinal Health.
Mistry worked previously with Diosynth Biotechnology, Baxter Biotech and Arris Pharmaceutical Corporation. .